Sign inJoin waitlistJoin the waitlist

Thomas Imperiale

Medical Director, Margaret Mary Health · Indiana University School of Medicine

Credentials: · ·

History

Margaret Mary Health · Indiana University School of Medicine
Present
Indiana University School of Medicine
Present
Indiana University School of Medicine
Present

Yale University
1987–1988
Case Western Reserve University
1984–1987
Internal Medicine
1981–1984
New York University Grossman School of Medicine
1977–1981

Research

Multitarget stool DNA testing for colorectal-cancer screening
New England Journal of Medicine · 2014 · First of 8 authors · 1,420 citations
Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings
New England Journal of Medicine · 2000 · First of 6 authors · 814 citations
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population
New England Journal of Medicine · 2004 · First of 6 authors · 579 citations

Charles Kahi
25 papers
David Ransohoff
23 papers
Douglas Rex
19 papers
SS
Stuart Sherman
16 papers
John DeWitt
13 papers
TI
Timothy Imler
11 papers · 8 as a fellow
DR
Douglas Robertson
10 papers
Jason Dominitz
10 papers
PL
Paul Limburg
9 papers
AM
Arthur Mccullough
8 papers
DL
David Lieberman
8 papers
Hala Fatima
8 papers

Grants

Implementing Evidence Based Colorectal Cancer Screening in Rural Clinics
National Cancer Institute · R01
PI · $2.7M · Indiana University Indianapolis
2023–2027
Prevalence, Risk Factors and Outcomes of Post-Colonoscopy Colorectal Cancer in Veterans
Department of Veterans Affairs · I01
Contact PI · Rlr Va Medical Center
2018–2023
Estimating Risk of Sporadic Colorectal Cancer in Veterans Under Age 50
Department of Veterans Affairs · I01
Contact PI · Rlr Va Medical Center
2016–2020
Quantifying Risk to Target Screening Colonoscopy
National Cancer Institute · R01
Contact PI · $2.6M · Indiana University Indianapolis
2004–2011

Clinical trials

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"
Principal investigator · Completed
Exact Sciences Corporation
2019–2023
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"
Principal investigator · Completed
Exact Sciences Corporation
2019–2023
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.
Principal investigator · Completed
Exact Sciences Corporation
2018–2019
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
Principal investigator · Completed
Exact Sciences Corporation
2018–2019